The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 2863-2872

  Iczkowski, Kenneth A ^a,b   Omara Opyene, A Levi ^a   Shah, Girish V ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Adhesion; CD44; Invasion; Prostate cancer

Indexed keywords

CALCITONIN; CALCITONIN RECEPTOR; CD44V ANTIGEN; FIBRONECTIN; HERMES ANTIGEN; HYALURONIC ACID; MESSENGER RNA;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL ADHESION; CONTROLLED STUDY; EXON; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALTERNATIVE SPLICING; ANTIGENS, CD44; CALCITONIN; CELL ADHESION; CELL LINE, TUMOR; FIBRONECTINS; GENE SILENCING; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, CALCITONIN; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 33746731655     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lesley J, English N, Charles C and Hyman R: The role of the CD44 cytoplasmic and transmembrane domains in constitutive and inducible hyaluronan binding. Eur J Immunol 30: 245-253, 2000.
2. Lesley J, Kincade PW and Hyman R: Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibody. Eur J Immunol 23: 1902-1909, 1993.
3. Miyake H, Hara I, Okamoto I, Gohji K, Yamanaka K, Arakawa S, Saya H and Kamidono S: Interaction between CD44 and hyaluronic acid regulates human prostate cancer development. J Urol 160: 1562-1566, 1998.
4. Terpe H-J, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K and Gunthert U: Expression of CD44 isoforms in renal cell tumors. Am J Pathol 148: 453-463, 1996.
5. Yamaguchi A, Urano T, Goi T, Saito M, Takeuchi K and Hirose K: Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 14: 1122-1127, 1996.
6. Rall CJ and Rustgi AK: CD44 isoform expression in primary and metastatic pancreatic adenocarcinoma. Cancer Res 55: 1831-1835, 1995.
7. Woodman AC, Sugiyama M, Yoshida K, Sugino T, Borgya A and Goodison S: Analysis of anomalous CD44 gene expression in human breast, bladder and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol 149: 1519-1530, 1996.
8. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Greth U and Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89: 12160-12164, 1992.
9. Yoshida K, Goodison S, Sugino T, Bolodeoku J, Churchman M, Warren BF and Tarin D: Semiquantitative detection of abnormal CD44 transcripts in colon carcinomas by reverse transcription-polymerase chain reaction enzyme-linked immunosorbent assay: RT-PCR ELISA. Mol Diagn 1: 167-173, 1996.
10. Iczkowski KA, Pantazis CG and Collins J: The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. J Urol Pathol 6: 119-129, 1997.
11. Vis AN, van Rhijn BW, Noordzij MA, Schroder FH and van der Kwast TH: Value of tissue markers p27, kip1, MIB-1 and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol 197: 148-154, 2002.
12. Kallakury BV, Sheehan CE and Ross JS: Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin and CD44 in prostatic adenocarcinomas. Hum Pathol 32: 849-855, 2001.
13. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH and van der Kwast TH: Prognostic value of cell cycle proteins p27, kip1 and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 164: 2156-2161, 2000.
14. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI and Miller GJ: CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate 34: 162-168, 1998.
15. Iczkowski KA, Bai S and Pantazis CG: Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res 23: 3129-3140, 2003.
16. Omara-Opyene AL, Qiu J, Shah G and Iczkowski KA: Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 84: 894-907, 2004.
17. sα in proliferation of PC-3M prostate cancer cells. Int J Cancer 91: 46-54, 2001.
18. sαxQL-medicated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene 18: 3376-3382, 1999.
19. Iczkowski KA, Omara-Opyene AL, Pansara M and Shah GV: Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion. Anticancer Res 25: 2075-2084, 2005.
20. Iczkowski KA, Omara-Opyene AL and Klösel R: Metafectene is superior to Lipofectamine in the transfection of Gsα prostate cancer cells. Mol Biotechnol 28: 97-103, 2004.
21. Wu G-J, Wu M-W H, Wang S-W, Liu Z, Qu P, Peng Q and Amin M: Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 overexpression in prostate cancer cell lines and tissues with malignant progression. Gene 279: 17-31, 2001.
22. Kozak M: Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem 266: 19867-19870, 1991.
23. Harada N, Mizoi T, Kinouchi M, Hoshi S, Shiiba K, Sasaki I and Matsuno S: Introduction of antisense CD44s cDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 91: 67-75, 2001.
24. Ponta H, Sherman L and Herrlich PA: CD44: from adhesion molecules to signaling regulators. Nature Rev Mol Cell Biol 4: 33-45, 2003.
25. Miletti KE, Saglimbeni GN, Chen S and Rodriguez-Rodriguez L: CD44 up-regulates the expression of matrix metalloproteases. MMPs in ovarian and breast carcinoma cells. Cancer Res 45: 418 (abstract), 2004.
26. Lipponen P, Aaltomaa S, Tammi R, Tammi M, Agren U and Kosma VM: High stromal hyaluronan level is assocated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 37: 849-856, 2001.
27. Bourguignon LYW, Zhu D and Zhu H: CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci 3: D637-649, 1998.
28. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, Wong AJ and Saya H: Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 155: 755-762, 2001.
29. Wu GJ, Peng Q, Fu P, Wang SW, Chiang CF, Dillehay DL and Wu MW: Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells. Gene 327: 201-213, 2004.
30. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S and Dubinett SM: Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloprotease-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 277: 50828-50833, 2002.
31. Lokeshwar VB, Rubinowicz D, Schroieder GL, Forgacs E, Minna JD, Block NL, Nadji M and Lokeshwar BL: Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 276: 11922-11932, 2001.
32. Aaltomaa S, Lipponen P, Tammi R, Tammi M, Viitanen J, Kankkunen JP and Kosma VM: Strong stromal hyaluronan expression is associated with PSA recurrence in local prostate cancer. Urol Int 69: 266-272, 2002.
33. Simpson MA, Wilson CM, Furcht LT, Spicer AP and Oegema TR: Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells. J Biol Chem 277: 10050-10057, 2002.
34. Tozawa K, Yamada Y, Kawai N, Okamura T, Ueda K and Kohri K: Osteopontin expression in prostate cancer and benign prostatic hyperplasia. Urol Int 62: 155-158, 1999.
35. Bates RC, Elith CA, Thorne RF and Burns GF: Engagement of variant CD44 confers resistance to anti-integrin antibody-mediated apoptosis in a colon carcinoma cell line. Cell Adhes Commun 6: 21-38, 1998.
36. Brenner W, Groß S, Steinbach F, Horn S, Hohenfellner R and Thuroff JW: Differential inhibition of renal cancer invasion mediated by fibronectin, collagen IV and laminin. Cancer Lett 155: 199-205, 2000.
37. 1 integrin mediate ovarian carcinoma cell migration toward extracellular matrix protein. Clin Exp Metast 18: 67-75, 2000.
38. Ponta H, Sherman L and Herrlich PA: CD44: from adhesion molecules to signaling regulators. Nature Rev Mol Cell Biol 4: 33-45, 2003.
39. Sabbisetti V, Chigurupati S, Thomas S and Shah G: Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion. Int J Cancer 118: 2694-2702, 2006.
40. Lee H-Y, Oh S-H, Suh Y-A, Baek JH, Papadimitrakopoulou V, Huang S and Hong WK: Response of non-small cell lung cancer cells to inhibitors of phoshpatidyl 3-kinase/Akt & MAP kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 11: 6065-6074, 2005.